Neurostar TMS therapy (Neuronetics) success in Depression

Patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving NeuroStar TMS Therapy from Neuronetics achieved significant improvements in both depression symptoms and in quality of life measurements. Overall, 58 percent of patients achieved a positive response to NeuroStar TMS therapy, with 37 percent of patients achieving remission from their depression. After an average of five weeks of NeuroStar treatment, the percentage of patients reporting extreme problems with anxiety and depression decreased by 42.2 percent, demonstrating a reduction in depression symptomatology. For overall treatment effect, the percentage of patients reporting no problems in performing usual activities improved by 30.5 percent. Results were presented at the annual meeting of the American Psychiatric Association